Oncogenic activation of the mesenchymal epithelial transition factor (MET) gene in NSCLC can occur mainly by amplification (1–5%) or by the presence of mutations in exon 14 (3–4%) that reduce degradation of the MET protein [9]. Here, MET is linked to non-small cell lung carcinoma.